Long-term stability of diluted solutions of the monoclonal antibody rituximab.
As it is an important challenge for pharmacists to access the stability of monoclonal antibodies because of the widespread of centralized preparation units, we conducted a study to evaluate the physicochemical and biological stability of diluted rituximab at 1mg/mL over six months at 4 °C. We also conducted the study at 40 °C to demonstrate that all methods employed were stability indicating. Various protein characterization methods were used to determine changes in physicochemical properties of rituximab, including size-exclusion chromatography, dynamic light scattering, turbidimetry, cation-exchange chromatography, second-derivative ultraviolet and infrared spectroscopy, and peptide mapping. Cell culture was used to assess biological stability. We demonstrated that diluted rituximab stored at 4 °C in polyolefine bags remained stable for at least six months. No physical or chemical instability was observed, and the biological activity was fully maintained. Size exclusion chromatography did not show polymerization or fragmentation. No difference was noticed in the hydrodynamic diameter of RTX. No additional peak or decrease in the areas under curve was found by cation exchange chromatography. The thermal aggregation curves and their derived thermodynamic parameters were unchanged. The primary, secondary and tertiary structures of the protein were not modified. Finally, the direct cytotoxic effect of rituximab was fully maintained.
APHP, GH Henri Mondor, Département de Pharmacie, Unité Pharmaceutique de Recherche en Essais Cliniques, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. muriel.paul@hmn.aphp.fr
Muriel
M
Paul
Victoire
V
Vieillard
Emmanuel
E
Jaccoulet
Alain
A
Astier
D058846:Antibodies, Monoclonal, Murine-Derived / Q000737:chemistry* / Q000633:toxicity; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000633:toxicity; D018501:Antirheumatic Agents / Q000737:chemistry* / Q000633:toxicity; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002850:Chromatography, Gel; D004355:Drug Stability; D006801:Humans; D009391:Nephelometry and Turbidimetry; D000069283:Rituximab; D012996:Solutions; D017550:Spectroscopy, Fourier Transform Infrared
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D012996:Solutions; D000069283:Rituximab